Cardiol Therapeutics Inc. (TSX:CRDL)
Canada
· Delayed Price · Currency is CAD 1.490
-0.015 (-1.01%)
Apr 28, 2025, 4:00 PM EDT
Cardiol Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
123.09M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.64B |
| dentalcorp Holdings | 1.55B |
| Sienna Senior Living | 893.16M |
| Trulieve Cannabis | 1.71B |
| Extendicare | 1.47B |
| WELL Health Technologies | 919.69M |
| Curaleaf Holdings | 1.93B |
| Cronos Group | 169.23M |
Cardiol Therapeutics News
- 12 days ago - Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 27 days ago - Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile Corp
- 2 months ago - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
- 2 months ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha
- 2 months ago - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 4 months ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire
- 5 months ago - CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga